ALPS Advisors’s Innate Pharma IPHA Stock Holding History

ALPS Advisors’s Portfolio IPHA Stock Details IPHA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-83,966	Closed	-$282K	–	1065
2022 Q1	$282K	Sell	83,966 -9,752	-10%	-$36K	﹤0.01%	776
2021 Q4	$429K	Buy	+93,718	New	+$499K	﹤0.01%	591

Other funds holding IPHA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

ALPS Advisors's IPHA Position: Q2 2022 in Review

ALPS Advisors sold out of Innate Pharma (IPHA) in Q2 2022, closing a stake of 83,966 shares — an estimated $282K sold.

ALPS Advisors first reported a position in IPHA in Q4 2021 and held it in 2 quarters. The position peaked at $429K in Q4 2021. 13 funds tracked by Wall St. Rank hold IPHA as of Q2 2022.

ALPS Advisors reported no remaining Innate Pharma position as of Q2 2022 after selling out during the quarter.
ALPS Advisors sold 83,966 Innate Pharma shares in Q2 2022, an estimated $282K.
ALPS Advisors first reported a position in Innate Pharma in Q4 2021 and held it in 2 quarters.
ALPS Advisors's Innate Pharma position peaked at $429K in Q4 2021.
13 funds tracked by Wall St. Rank held Innate Pharma as of Q2 2022.

Based on ALPS Advisors's 13F filing for Q2 2022, filed 11 Aug 2022.